The effect of atrial natriuretic factor (ANF) on adenylate cyclase activity was studied in rat platelet membranes. ANF- (99-126)-, -(101-126)-, -(103-126)-and -(103-123) 
INTRODUCTION
Atrial natriuretic factor (ANF) from mammalian atria have been reported to exhibit a variety of physiological effects, including diuresis, natriuresis, vasorelaxation, inhibition of aldosterone secretion from adrenal cortex and inhibition of vasopressin and renin release [1] . ANF has been reported to stimulate guanylate cyclase/cyclic GMP [2, 3] and to inhibit the adenylate cyclase/cyclic AMP system in several tissues [4] [5] [6] [7] [8] [9] [10] [11] , suggesting that these two second-messenger systems may be responsible in mediating the physiological responses of ANF. By using affinity cross-linking techniques [12] or photo-affinity labelling [13] , at least two classes of ANF receptors have been shown to be present in several tissues [12] [13] [14] [15] . These are of high (130000) and low (66000) Mr and have been designated 'ANF-R1 ' and 'ANF-R2' receptors respectively [12] . ANF-RI receptors contain an intrinsic particulate guanylate cyclase [12] , whereas ANF-R2 receptors have been shown to be non-guanylate-cyclase-coupled. Recently, Maack and his colleagues [16] have demonstrated that ANF-R2 receptors are biologically silent receptors (the primary function of these receptors is the sequestration and metabolic clearance of ANF) and they have therefore designated them 'clearance receptors' (C-ANF receptors). However, we have ANF-(99-126)-peptide, ANF-(101-126)-peptide and ANF-(103-123)-peptide and atriopeptin I were kindly provided by Bio-Mega, Laval, Quebec, Canada.
Methods
Preparation of platelet membranes. Rat platelet membranes were prepared with minor modifications of the method described by Schiffrin et al. [18] . Blood was drawn from femoral arteries of anaesthetized rats into citrate anticoagulant (87 mM-sodium citrate/105 mM-dextrose/ll mM-citric acid/7 mM-Na3PO4). A 1 ml portion of anticoagulant was used for each 10 ml of blood. After centrifugation of whole blood at 350 g for 10 min, plateletenriched plasma was collected and further centrifuged at 1000 g for 10 min. Pellet was washed twice with a buffer containing 10 mM-Tris and 1 mM-EDTA, pH 7.5. Platelet suspensions in 10 mM-Tris and 1 mM-EDTA were frozen in liquid N2 and stored at -70 'C. Before the assay, the frozen platelet suspension was thawed and homogenized, and this freeze-thawing was repeated twice. This preparation was used for adenylate cyclase and ANFreceptor binding studies.
ANF-receptor binding determination. 1251I-ANF binding was determined at 25 'C by incubating 20,ul of membranes or cell suspension ( 100 ,ug) for 60 min with 10 pM-'25I-ANF-(99-126)-peptide (sp. radioactivity 1000 Ci/mmol) in 200#1d of a reaction mixture consisting of 50 mM-Tris/HCI, pH 7.5, 5 mM-MgCl2, 1 mM-aprotinin, bacitracin (1 mg/ml), BSA (4 mg/ml) 0.5 mmphenylmethanesulphonyl fluoride and various amounts of the competing ligands when used. Non-specific binding was determined by using 0.1 M unlabelled ANF-(99-126)-peptide. Binding reactions were initiated by the addition of membrane protein. The receptor-1251-ANF complex was separated from free 121I-ANF by filtration through GF/C filters pretreated with polyethyleneimine. The filters were washed three times with 4 ml of ice-cold Tris/HCl buffer, pH 7.5, and radioactivity was counted in a y-radiation counter.
Affinity cross-linking of ANF. The affinity cross-linking was performed essentially as described by Leitman et al. [12] , with slight modification. The platelet suspension was incubated at 25 
and boiled for 5 min. The solubilized proteins were electrophoresed using 7.5 % separating gels as described previously [20] .
The gels were fixed, stained, destained, dried and autoradiographed by exposing to Kodak XAR-5 film as described previously [20] .
Pertussis-toxin (PT) treatment. The PT treatment was performed as described previously [20] . The (30-70 ,ug) to the reaction mixture, which had been thermally equilibrated for 2 min at 37 'C. Reactions were conducted in triplicate for 10 min at 37 'C. Reactions were terminated by the addition of 0.6 ml of 120 mM-zinc acetate. Cyclic AMP was purified by co-precipitation of other nucleotides with ZnCO3 by the addition of 0.5 ml of 144 mM-Na2CO3 and subsequent chromatography by the double-column system described by Salomon et al. [22] . To investigate the effect of amiloride treatment on the ANF-mediated inhibition of adenylate cyclase, the platelet membranes were preincubated at 37 'C for 10 min without or with 100 ,uM-amiloride and various concentrations of ANF. This concentration of amiloride has been shown (1) to attenuate completely the inhibitory effects of hormones on adenylate cyclase activity and (2) to inhibit the labelling of PT-catalysed ADP-ribosylation of the inhibitory guanine-nucleotide-regulatory protein G, [23] . After 10 min preincubation, the adenylate cyclase reaction was initiated with the addition of reaction mixture to the membranes. The reactions were conducted in triplicate for 10 min at 37 'C and were terminated as described above. Protein was determined essentially as described by Lowry et al. [24] , with crystalline BSA as standard.
Determination of cyclic AMP levels. Cyclic AMP levels in platelets were determined by radioimmunoassay as described previously [17] by using a radioimmunoassay kit from du Pont (Mississauga, Ontario, Canada).
RESULTS

Binding of 1251-ANF to rat platelet membranes
The presence of ANF receptors in human platelets has been demonstrated previously [18] . To investigate whether ANFbinding sites are also present in rat platelets, the binding activity was studied using 125I-ANF-(99-126)-peptide. As illustrated in Fig. 1 Effect of ANF on adenylate cyclase activity and cyclic AMP levels
In order to investigate whether the ANF receptors present in rat platelets are functional and are coupled to adenylate cyclase system, the effects on adenylate cyclase activity of various analogues of ANF which were used for binding studies were examined. As shown in Gln'8-Ser'l-Gln20-Leu2'-Gly22-ANF-(4-23)-peptide-NH2] which binds with high affinity to ANF-R2 receptor only [16] and inhibits the adenylate cyclase/cyclic AMP system [17] , was also able to inhibit adenylate cyclase activity in rat platelets. The maximal inhibition observed was about 55 %, with an apparent K, of about l0-8 M (results not shown). In addition, the effect of ANF-(99-126)-peptide on cyclic AMP levels was also studied, and the results are shown in Table 1 . As reported previously for other tissues [8, 17] , ANF also decreased cyclic AMP levels in rat platelets. The maximal inhibition observed was between 40 and 50%. Table 1 . Effect of ANF-(99-126)-peptide on cyclic AMP levels in rat platelets Cyclic AMP levels in platelets were determined as described in the Experimental section. Platelets were preincubated with 1 mm-isobutylmethylxanthine for 5 min at 37°C, ANF-(99-126)-peptide was added to the platelets at different concentrations and were further incubated for 10 min. The reaction was stopped by the addition of 12 % trichloroacetic acid (final concn. 6 %), and cyclic AMP levels in the supernatant were determined by using a radioimmunoassay kit from du Pont. Values are means +S.E.M. for three separate experiments. The inhibitory effect was also dependent on the presence of guanine nucleotides, as shown in Fig. 4 Effect of amiloride and PT on ANF-mediated inhibition of adenylate cyclase
We have recently shown that amiloride interacts with G,-protein and results in the attenuation of the inhibitory responses of hormones on adenylate cyclase activity in rat aorta and anterior pituitary [23] . In the present studies we have used amiloride in addition to PT to investigate the involvement of G,-protein in the coupling of ANF receptors to adenylate cyclase in rat platelets. Fig. 5 shows that ANF-mediated inhibition of adenylate cyclase was completely abolished by amiloride (Fig.   1991 [20, 27] . In addition, amiloride, as was shown previously for zonaglomerulosa cells [28] , also enhanced the ANF binding in platelets by about 2-fold (results not shown), indicating that this may be the characteristic feature of amiloride action on ANF binding.
Various hormones have been reported to play an important role in platelet functions through the stimulation of the adenylate cyclase/cyclic AMP system [29] . It was of interest to examine whether ANF can modulate the stimulatory responses of hormones on adenylate cyclase activity. Fig. 6 demonstrates that NECA, prostaglandin E1, isoprenaline and forskolin stimulated adenylate cyclase activity to various extents, and ANF (10-7 M) inhibited the stimulatory effect of all these agonists; however, the stimulations were not completely abolished.
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Cross-linking studies To determine whether rat platelets possess multiple binding sites for ANF, 125I-ANF-(99-126)-peptide was covalently crosslinked to intact platelets with the bifunctional reagent disuccinimidyl suberate in the absence or presence of 1 UM unlabelled ANF-(99-126)-peptide, and the cellular proteins were then separated by SDS/PAGE. Fig. 7 demonstrates that 125I-ANF labelled predominantly one binding site of Mr about 66000, which was completely displaced by unlabelled ANF. About 60-70 % inhibition in the labelling of this protein band was also observed by 10 nm unlabelled ANF (results not shown). These results indicate that rat platelets possess only the type of ANF receptors designated 'ANF-R2' [12] .
DISCUSSION
In the present study we demonstrate the presence of ANFbinding sites in rat platelet membranes. Unlike adrenal zonaglomerulosa cells, where both high-and low-affinity binding sites for ANF have been shown to be present [30] , the binding of 125_. ANF to rat platelet membranes revealed a single class of specific binding sites. The presence of single class of ANF-binding sites has also been reported in several tissues, including human platelets [18, 31] . The binding affinity (Kd -120 pM) observed in rat platelet membranes was found to be over a similar range to that demonstrated in several other tissues [18, 31, 32] . In addition, the unlabelled peptides ANF-(99-126)-peptide, ANF-(101-126)-peptide, ANF-(103-123)-peptide and ANF-(103-126)-peptide inhibited the binding of the labelled ANF-(99-126)-peptide in rat platelets in a manner similar to that reported in other tissues, including human platelets [18] . ANF at physiological concentrations has been reported to inhibit adenylate cyclase and cyclic AMP levels in numerous tissues [4, [7] [8] [9] [10] [11] . The inhibition of this signal-transduction system by ANF may be one of the important mechanisms through which ANF exerts its physiological responses, such as inhibition of aldosterone secretion [33] , inhibition of renin release [33] , inhibition of vasopressin release [34] and inhibition of progesterone secretion [36] . In the present study we demonstrate that various analogues of ANF that inhibited the binding of radiolabelled ANF also inhibited the adenylate cyclase activity in an analogous manner: ANF-(103-123)-peptide was the most potent, and ANF-(103-126)-peptide the least potent. The maximal inhibitions observed were between 30 and 55 %, which were similar to those reported for other tissues, such as glomeruli, vascular smooth-muscle cells and pituitary [4, 7, 9] . The apparent As reported in other tissues [7, 8, 27] , the inhibition of adenylate cyclase by ANF in rat platelets was also dependent on the presence of guanine nucleotides, indicating that ANF receptors are coupled to adenylate cyclase system by guanine-nucleotideregulatory protein. The involvement of G1 in the coupling of ANF receptors to adenylate cyclase was demonstrated previously [20, 27] . In the present studies, amiloride and PT were also able to attenuate the ANF-mediated inhibition of adenylate cyclase, which strongly suggests that ANF receptors in platelets are also coupled to adenylate cyclase system through a G,-protein.
Cyclic AMP plays an important role in a variety of physiological functions, including platelet aggregation. Various hormones which stimulate the adenylate cyclase/cyclic AMP system 215 are inhibitors of platelet aggregation [29] . In the present studies, we demonstrate that NECA, isoprenaline, prostaglandin E1 and forskolin stimulated adenylate cyclase to various extents, and ANF, as in other tissues [4, [7] [8] [9] [10] [11] , inhibited the stimulatory effects ofall these agents in platelets also. However, contradictory effects of ANF on platelet aggregation have also been demonstrated. ANF has been shown to have no effect on platelet aggregation, whereas Loeb & Gaer [37] have recently reported that ANF potentiated the platelet aggregation induced by thrombin, ADP and adrenaline (epinephrine). Taken together, these results may indicate that the inhibition of adenylate cyclase activity by ANF may be one of the possible mechanisms responsible for the potentiation of platelet aggregation.
ANF has also been demonstrated to stimulate particulate guanylate cyclase activity and cyclic GMP levels in a variety of tissues [2] , with the exception of platelets, which have been reported to be devoid of particulate guanylate cyclase activity [19] . It is also known that some, but not all, the physiological effects ofANF are mediated through stimulation of the guanylate cyclase/cyclic GMP system. By using affinity cross-linking studies, or photoaffinity-labelling techniques, two classes of ANF receptors have been shown to be present in various tissues [12, 13] . These receptors have M, values of 130000-140000 and 66000 and are designated 'ANF-R1' and 'ANF-R2/C' [12, 16] respectively. The 130000-Mr receptors, ANF-R1, are known to be coupled to guanylate cyclase activity, whereas ANF-R2/C receptors are coupled to the adenylate cyclase/cyclic AMP system [17] . As expected, in the present studies, by using the affinity cross-linking labelling technique, we demonstrate specific predominant labelling of a single protein band of Mr about 66000 in rat platelets, which was completely inhibited in the presence of unlabelled ANF, indicating that rat platelets lack ANF-R1 receptors and possess only ANF-R2 receptors. These findings accord very well with a previous report indicating a lack of ANF effect on cyclic GMP levels and the absence of particulate guanylate cyclase in platelets [19] . Since ANF inhibits adenylate cyclase activity in the platelet membranes, it clearly indicates that the ANF-R2 receptors are associated with the adenylate cyclase/ cyclic AMP signal-transduction system and further supports our previous results [17] . Recently Tseng et al. [38] have demonstrated that ANF inhibited cyclic AMP generation and thyroglobulin secretion without increasing cyclic GMP levels in human cultured thyroid cells, which have only ANF-R2 receptor subtypes. In addition C-ANF4-23, which interacts with ANF-R2 receptors, has also been reported to inhibit cyclic AMP levels and adrenergic neurotransmission independent of guanylate cyclase in nervegrowth-factor-treated pheochromocytoma cells [39] . We have also reported recently that C-ANF4 23 inhibited luteinizinghormone-stimulated progesterone secretion in mouse Leydig tumour cells [17] . Taken together, it may be suggested that the potentiating effect of ANF on adrenaline, thrombin and ADP on platelet aggregation may be mediated through ANF-R2 receptors present in platelets and which are associated with the adenylate cyclase/cyclic AMP signal-transduction system. ANF has also been shown to inhibit the formation of inositol phosphates [40] , an effect that can be mimicked by 8-bromo cyclic GMP and may thus be mediated through the occupancy of the ANF-R1 receptors. On the other hand, recently, ANF has also been reported to stimulate the Ptdlns turnover in the presence of guanine nucleotides in bovine aortic smooth-muscle cells, which has been demonstrated to be through its interaction with ANF-R2 receptors [40] . Thus it is possible that receptors may be coupled to two different intracellular messengers, cyclic AMP and PtdIns turnover, or there may exist a 'cross-talk' between these two second messengers. It is well known that the hormones such as angiotensin II, vasopressin and acetylcholine, which inhibit the adenylate cyclase/cyclic AMP system, also stimulate Ptdlns turnover [41] , and the hormones which increase cyclic AMP are inhibitors of PtdIns turnover [42] . In the light of these observations, it is possible that the decrease in cyclic AMP by ANF may be responsible for stimulating Ptdlns turnover. In other words, the stimulation of Ptdlns turnover by ANF in cultured vascular cells [40] may be the secondary event and mediated through the adenylate cyclase/ cyclic AMP system to which are coupled the ANF-R2 receptors.
In conclusion, our present studies demonstrate that rat platelets only have ANF-R2 subtype receptors, which are coupled to the adenylate cyclase/cyclic AMP signal-transduction system. Whether activation of this signal-transduction system by ANF is associated with Ptdlns turnover requires thorough investigation.
